



## **Hydra Biosciences to Present at the 8<sup>th</sup> Annual Biotech Showcase Conference in San Francisco on Jan. 11**

**January 6, 2016 – Cambridge, MA** – [Hydra Biosciences](#), a leader in the field of Transient Receptor Potential (TRP) ion channel modulation in the areas of pain, inflammation, renal disease, anxiety and pulmonary disease, today announced that Russell Herndon, President and CEO, will provide a company update at the 8<sup>th</sup> Annual Biotech Showcase conference in San Francisco. The presentation is at the [Parc 55 Hilton Hotel](#) on Jan. 11, 2016, at 3:15 p.m. PST in the Davidson room.

Herndon's presentation will include an update on the Company and the clinical development of HX-100, a TRPA1 antagonist, which is entering phase 2 studies for the treatment of diabetic neuropathic pain and allergic asthma in 2016. HX-100 is a highly selective, potent inhibitor of TRPA1, a novel target being studied as a potential treatment of painful diabetic neuropathy and allergic asthma. HX-100 can be taken orally, and it is expected to have robust efficacy without abuse liabilities, given the limited expression of TRPA1 in the brain. Data from a phase 1 safety is expected in early 2016.

[Biotech Showcase™](#) is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and potential strategic partners in one place during the course of one of the industry's largest annual healthcare investor conferences. Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group.

### **About Hydra Biosciences**

Hydra Biosciences is a privately held biopharmaceutical company based in Cambridge, Massachusetts, that develops drugs to treat pain, inflammation, renal disease, anxiety and pulmonary disease using its expertise in novel ion channels. Hydra Biosciences' proprietary platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. More information about Hydra Biosciences is available at: [www.hydrabiosciences.com](http://www.hydrabiosciences.com).

###

### **Corporate:**

Russell Herndon  
Hydra Biosciences  
617-494-5230 x3352

### **Media Contact:**

David Connolly  
LaVoieHealthScience  
617-374-8800, Ext. 108  
[dconnolly@lavoiehealthscience.com](mailto:dconnolly@lavoiehealthscience.com)